ApoGlyx
#Aquaporin
#Biotechnology
#Drug Discovery
#Sepsis
#Type 2 diabetes
Overview
Apoglyx is a pre-clinical stage biotech company with the aim to develop a small molecule therapy for sepsis, and further indications, based on inhibition of Aquaporin-9.
Apoglyx was founded based on research from Aarhus University (DK), Aalborg University (DK), and Lund University (S).
Contact Details
pbn@apoglyx.com
Lund, Sweden
Founded
2015
Employees
2-10
Categories
Keywords
#Aquaporin
#Biotechnology
#Drug Discovery
#Sepsis
#Type 2 diabetes
Companies teams usually look at after ApoGlyx
Comparing a few options usually leads to better decisions
Save companies to compare later. Useful when sharing options with your team
This is how your company profile looks to others.